GSK to sell ofatumumab rights to Novartis for $1B
Permalink

GSK to sell ofatumumab rights to Novartis for $1B

Novartis ($NVS) is paying GlaxoSmithKline ($GSK) as much as $1 billion for the rights to…

Continue Reading →